COVID-19 Vaccine 3rd Dose for Immunocompromised
3rd COVID-19 Vaccine Dose Recommended for Immunocompromised Patients
People who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. The CDC recommends that moderately to severely immunocompromised persons receive an additional COVID-19 vaccine does if they received the Pfizer or Moderna vaccine.
How to obtain a 3rd dose of COVID-19 vaccine if eligible:
- Inquire about the 3rd dose at a scheduled appointment.
- Or, contact us via your patient portal account to inquire about eligibility.
Please note: The 3rd dose should be the same vaccine product (Pfizer for Pfizer, or Moderna for Moderna) as the initial 2-dose COVID-19 vaccine series. The Family Health Centers can offer a 3rd dose of the Pfizer vaccine at this time. The additional dose must be administered 28 days+ after the initial COVID-19 vaccine series. This does not apply to patients who received the single-dose Johnson & Johnson COVID-19 vaccine – please stay tuned for more information if you received the J&J COVID-19 vaccine.
You are eligible for the 3rd Vaccine Dose if one or more of the following applies to you:
1. Been receiving active cancer treatment for tumors or cancers of the blood
2. Received an organ transplant and are taking medicine to suppress the immune system
3. Received a stem cell transplant within the last 2 years
4. Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
5. Advanced or untreated HIV infection (i.e., AIDS)
6. Active treatment with high-dose steroids or other drugs that may suppress your immune response, including:
o prednisone (Deltasone, Orasone)
o dexamethasone
o budesonide (Entocort EC)
o prednisolone (Millipred)
o tofacitinib (Xeljanz)
o cyclosporine (Neoral, Sandimmune, SangCya)
o tacrolimus (Astagraf XL, Envarsus XR, Prograf)
o sirolimus (Rapamune)
o everolimus (Afinitor, Zortress)
o azathioprine (Azasan, Imuran)
o leflunomide (Arava)
o mycophenolate (CellCept, Myfortic)
o abatacept (Orencia)
o adalimumab (Humira)
o anakinra (Kineret)
o certolizumab (Cimzia)
o etanercept (Enbrel)
o golimumab (Simponi)
o infliximab (Remicade)
o ixekizumab (Taltz)
o natalizumab (Tysabri)
o rituximab (Rituxan)
o secukinumab (Cosentyx)
o tocilizumab (Actemra)
o ustekinumab (Stelara)
o vedolizumab (Entyvio)
o basiliximab (Simulect)
o daclizumab (Zinbryta)